Estrella shares surge 15.12% after-hours as EB103 advances to Phase II trials following positive DSMB recommendation.

Estrella Immunopharma (NASDAQ: ESLA) surged 15.12% in after-hours trading following news that its EB103 therapy advanced to Phase II trials after a favorable Data Safety Monitoring Board (DSMB) review. The DSMB confirmed a 100% complete response rate at Month 1 in the high-dose cohort of Phase I, with no treatment-related serious adverse events reported, even among high-risk patients. The recommendation to proceed to Phase II underscores EB103’s potential as a best-in-class CD19 CAR-T therapy, with the company highlighting its ability to address patients ineligible for current commercial products. The trial’s expansion phase will evaluate safety and efficacy in a broader relapsed/refractory B-cell NHL population, positioning Estrella to advance its lead candidate toward pivotal trials. The announcement reinforced optimism about EB103’s commercial potential and safety profile, directly driving the sharp post-market rally.